"The addition of Dr. Samer Kaba strengthens the Medpace position, supporting our sponsors who are advancing new drugs for central nervous system diseases, one of the largest groups of drugs currently in development by biopharmaceutical sponsors," said Jonathan Isaacsohn, MD, FACC, Executive Vice President, Medpace. "Dr. Kaba’s experience and industry knowledge will allow us to provide strategic consultation to our sponsors in designing innovative clinical trial methods for many of our customers engaged in bringing new drugs to market in this therapeutic area."
Prior to joining Medpace, Dr. Kaba served as the VP of Clinical Development and Chief Medical Officer at Camargo Pharmaceutical Services, VP & Global Head of Medical Affairs and Strategic Product Development at Premier Research, and Sr. Director of Global Product Development at PRA International. In addition to his large expertise in drug development, Dr. Kaba has over 20 years experience in managing patients with neurological conditions.
Prior to joining the pharmaceutical industry, Dr. Kaba held multiple academic positions at the University of Texas and University of Arkansas, and maintained a neurology private practice. He continues to hold the position of Clinical Assistant Professor of Neurology at Emory University. Dr. Kaba completed his medical degree at the Damascus University School of Medicine in Syria, and his post-graduate work at the State University of New York at Buffalo. He also completed fellowship training in Neuro-immunology (Multiple Sclerosis) at the State University of New York at Buffalo, and in Neuro-oncology at the University of Texas M.D. Anderson Cancer Center, in Houston. Dr. Kaba is board-certified by the American Board of Psychiatry and Neurology. He is an active member of the American Academy of Neurology, Society for Neuro-Oncology, American Society of Clinical Oncology, and American Academy of Pharmaceutical Physicians. He has many scientific publications and book chapters to his credit, and has been an invited speaker at several scientific conferences.